Literature DB >> 3167206

The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients.

K I Mills1, E D MacKenzie, G D Birnie.   

Abstract

The Philadelphia (Ph1) chromosome, characteristic of chronic myelogenous leukemia (CML), arises from a reciprocal translocation between chromosomes 9 and 22. The site of the breakpoint on chromosome 22 is within a small region called the breakpoint cluster region (bcr). We have mapped the breakpoint within the bcr in peripheral blood leukocyte DNA from 22 Ph1-positive CML patients. No correlation between the site of the breakpoint and the clinical phase of the disease was found. However, a striking correlation between the site of the breakpoint and the length of time between presentation and onset of acute phase was observed: on average, patients with a 5' break-point had a fourfold longer chronic phase (median, 203 weeks) than those with a 3' breakpoint (median, 52 weeks).

Entities:  

Mesh:

Year:  1988        PMID: 3167206

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  Bone marrow transplantation. Part I--Allogeneic.

Authors:  N J Chao; K G Blume
Journal:  West J Med       Date:  1989-12

2.  Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: the value of early evaluation of the course of the disease. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.

Authors: 
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

3.  A study of the myeloid differentiation antigens of the peripheral blood neutrophil granulocytes in the different evolutive phases of chronic myeloid leukemia.

Authors:  M Rozman; F Cervantes; C Rozman
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

4.  Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia.

Authors:  A Grossman; R T Silver; Z Arlin; M Coleman; E Camposano; P Gascon; P A Benn
Journal:  Am J Hum Genet       Date:  1989-11       Impact factor: 11.025

5.  The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview.

Authors:  Michele Baccarani; Fausto Castagnetti; Gabriele Gugliotta; Gianantonio Rosti; Simona Soverini; Ali Albeer; Markus Pfirrmann
Journal:  Leukemia       Date:  2019-01-23       Impact factor: 11.528

Review 6.  Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia.

Authors:  Matteo Molica; Elisabetta Abruzzese; Massimo Breccia
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-09-01       Impact factor: 2.576

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.